DOCSLIB.ORG

On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension ORIGINAL INVESTIGATION On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension Robert H. Fagard, MD; Jan A. Staessen, MD; Lutgarde Thijs, MSc; Hilde Celis, MD; Christopher J. Bulpitt, MD; Peter W. de Leeuw, MD; Gastone Leonetti, MD; Jaakko Tuomilehto, MD; Yair Yodfat, MD Background: It has been suggested that low diastolic mortality, but not cardiovascular mortality, increased with blood pressure (BP) while receiving antihypertensive treat- low diastolic BP with active treatment (PϽ.005) and with ment (hereinafter called on-treatment BP) is harmful in placebo (PϽ.05); for example, hazard ratios for lower older patients with systolic hypertension. We examined diastolic BP, that is, 65 to 60 mm Hg, were, respectively, the association between on-treatment diastolic BP, mor- 1.15 (95% confidence interval, 1.00-1.31) and 1.28 (95% tality, and cardiovascular events in the prospective pla- confidence interval, 1.03-1.59). Low diastolic BP with ac- cebo-controlled Systolic Hypertension in Europe Trial. tive treatment was associated with increased risk of car- diovascular events, but only in patients with coronary Methods: Elderly patients with systolic hypertension heart disease at baseline (PϽ.02; hazard ratio for BP 65-60 were randomized into the double-blind first phase of the mm Hg, 1.17; 95% confidence interval, 0.98-1.38). trial, after which all patients received active study drugs (phase 2). We assessed the relationship between out- Conclusions: These findings support the hypothesis that come and on-treatment diastolic BP by use of multivar- antihypertensive treatment can be intensified to pre- iate Cox regression analysis during receipt of placebo vent cardiovascular events when systolic BP is not un- (phase 1) and during active treatment (phases 1 and 2). der control in older patients with systolic hypertension, at least until diastolic BP reaches 55 mm Hg. However, a Results: Rates of noncardiovascular mortality, cardio- prudent approach is warranted in patients with concomi- vascular mortality, and cardiovascular events were 11.1, tant coronary heart disease, in whom diastolic BP should 12.0, and 29.4, respectively, per 1000 patient-years with probably not be lowered to less than 70 mm Hg. active treatment (n=2358) and 11.9, 12.6, and 39.0, re- spectively, with placebo (n=2225). Noncardiovascular Arch Intern Med. 2007;167(17):1884-1891 HE EXISTENCE OF A J-CURVE tension and isolated systolic hypertension. relationship between mor- Therefore, the results may not apply to pa- tality or cardiovascular event tients with systolic hypertension who may and diastolic blood pres- be particularly vulnerable to low on- Author Affiliations: sure (BP) during antihyper- treatment diastolic BP, as shown in a post Hypertension and tensive treatment (hereinafter called on- hoc analysis of the Systolic Hypertension Cardiovascular Rehabilitation T Unit, University of Leuven, treatment BP) remains a matter of debate in the Elderly Program (SHEP), in which 1 Leuven, Belgium (Drs Fagard, in patients with hypertension. Apart from a J-curve was observed for incident car- Staessen, and Celis and intervention trials, in which patients are diovascular events during active treat- Ms Thijs); Imperial College, randomized to different target BP levels,2 ment but not during administration of pla- Hammersmith Hospital, placebo- or nontreatment-controlled trials cebo.15 The SHEP investigators concluded London, United Kingdom are probably the best way to evaluate the that it could be harmful to intensify anti- (Dr Bulpitt); University of J-curve. A large meta-analysis of indi- hypertensive therapy when diastolic BP has Maastricht, Maastricht, the 3-10 Netherlands (Dr de Leeuw); vidual patient data from 7 trials showed reached 70 mm Hg. In addition, the SHEP Istituto Auxologico Italiano, a higher incidence of cardiovascular death analysis did not stratify for coronary heart Ospedale San Luca, Milan, Italy with lower on-treatment diastolic BP, but disease (CHD) at baseline, whereas the risk (Dr Leonetti); National Public this relationship was also observed for non- of low on-treatment diastolic BP could be Health Institute and the cardiovascular death and similar relation- particularly high in patients with CHD.1,16 University of Helsinki, Helsinki, ships existed in the control patients; thus, Because of the far-reaching conse- Finland, and South the worse prognosis of lower diastolic BP quences of the conclusions from the SHEP Ostrobothnia Central Hospital, could not be solely ascribed to antihyper- trial, we analyzed the relationship be- Seina¨joki, Finland tensive treatment. A more recent meta- tween on-treatment diastolic BP, mortal- (Dr Tuomilehto); and 11 4-10,12-14 Department of Family analysis involving 10 trials con- ity, and cardiovascular events in older Medicine, Hadassah Medical cluded that lowering diastolic BP to less patients with systolic hypertension ran- School, Hebrew University of than 70 mm Hg did not cause harm. How- domized into the Systolic Hypertension in Jerusalem, Jerusalem, Israel ever, these meta-analyses did not differ- Europe (Syst-Eur) Trial12,17 and also ac- (Dr Yodfat). entiate between systolic-diastolic hyper- counted for CHD at baseline. (REPRINTED) ARCH INTERN MED/ VOL 167 (NO. 17), SEP 24, 2007 WWW.ARCHINTERNMED.COM 1884 ©2007 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 METHODS Table 1. Patient Characteristics at Baseline in the Placebo and Active Treatment Groupsa TRIAL DESIGN Active 12 The protocol of the Syst-Eur Trial was approved by the ethics Placebo Treatment committees of the University of Leuven, Leuven, Belgium, and Group Group participating centers; all subjects in the 198 centers gave in- Characteristic (n = 2225) (n = 2358) formed consent. Eligible patients had to be 60 years or older. Dur- Age, y 70.1 ± 6.6 70.2 ± 6.7 ing the run-in period with placebo, patients were seen at 3 base- Female sex 66.5 67.4 line visits 1 month apart. Data about medical history were collected, Body mass indexb 27.0 ± 4.0 27.0 ± 4.2 including history of CHD, which comprised myocardial infarc- Blood pressure, mm Hg tion and angina pectoris, based on supporting documents and ex- Systolic 173.9 ± 10.1 173.7 ± 9.8 aminations available to the local investigators. At each visit, BP Diastolic 85.5 ± 5.9 85.5 ± 5.8 was measured twice with a standard sphygmomanometer with Pulse rate, beats/min 73.0 ± 8.1 73.2 ± 7.9 the patient sitting. Patients were admitted to the double-blind phase Previous antihypertensive therapy 46.7 46.3 of the trial when they had an average run-in period systolic BP Previous cardiovascular complicationsc 30.3 29.4 of 160 to 219 mm Hg with diastolic BP less than 95 mm Hg. History of coronary heart diseasec 14.7 14.2 Patients were randomized to active medication or matched Diabetes 10.1 10.5 placebo groups. Active treatment consisted of nitrendipine (10- Current smoking 7.0 7.3 40 mg/d), which could be combined with or replaced by enala- Serum creatinine, mg/dL 1.0 ± 0.2 1.0 ± 0.2 pril maleate (5-20 mg/d) or hydrochlorothiazide (12.5-25 mg/d) Serum cholesterol, mg/dL 236 ± 46 231 ± 46 or both drugs, to reduce the sitting systolic BP by 20 mm Hg or more and to less than 150 mm Hg. At each 3-month visit, BP was SI conversion factors: To convert creatinine to millimoles per liter, multiply measured twice with the patient sitting and the 2 BP measure- by 88.4; cholesterol to millimoles per liter, multiply by 0.0259. a Data are given as mean ± SD or percentage. ments were averaged. When phase 1 of the Syst-Eur Trial was b Calculated as weight in kilograms divided by height in meters squared. stopped on February 14, 1997, after a median follow-up of 2.0 c Includes coronary heart disease (myocardial infarction and angina pectoris), years (range, 1 month to 8.1 years),12 patients in the control group heart failure, left ventricular hypertrophy, stroke, central nervous system. were switched to the active study treatment regimen and patients involvement, renal involvement, retinopathy grade 3, and aortic aneurysm. in the active treatment group continued receiving active treatment (phase 2).17 Visits were scheduled every 6 months in the study cen- ters and the same information was collected as during the double- ables with potential influence on BP and outcome, that is, age, blind phase of the trial. The extended follow-up ended on Decem- sex, smoking status, and previous antihypertensive treatment at ber 31, 2001. In the present analyses, follow-up data in the baseline, and weight, stroke, myocardial infarction, and diabetes placebo group are from phase 1 of the trial and follow-up data in mellitus both at baseline and as time-dependent covariates dur- the active treatment group are from phases 1 and 2. For patients ing follow-up. The analyses were performed with and without sys- who withdrew from the study or who could not be followed up tolic BP as a continuous time-dependent covariate. We plotted as planned, investigators collected data about vital status, occur- the adjusted hazard ratio (HR) vs on-treatment diastolic BP. The rence of diseases, and use of antihypertensive medication via yearly (adjusted HR−1)ϫ100 is the percent increase in risk associated telephone contact with patients, family members, or general 12,17 with the 5–mm Hg lower on-treatment diastolic BP. In the sec- practitioners. ond analysis, we calculated HRs in 5–mm Hg decrements of on- treatment diastolic BP, as in the SHEP study.15 For each cutoff OUTCOMES value, outcome was compared between patients with diastolic BP below that level and patients with diastolic BP at or above that Outcome measures were as follows: (1) fatal and nonfatal cere- level.
Load more

Recommended publications
  • High B1a0d Pressure and Its Treatment in General
    HIGH B1A0D PRESSURE AND ITS TREATMENT IN GENERAL PRACTICE WITH PARTICULAR REFERENCE TO A SERIES OF 100 CASES TREATED BY THE AUTHOR By HAROLD WILSON B01YBR IB.ffh.B. ProQuest Number: 13849841 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13849841 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 -CONTENTS SECTION 1. Introduction. SECTION 2. General Remarks. Definitions of General Interest. Present Views on Etiology. Pathology and Morbid Anatomy. Brief Historical Survey. SECTION 3. The Present Position. Prevalence. Clinical Manifestations. Prognosis. SECTION 4. Prevalence in Bolton. Summary of Cases. Symptomatology and Case Histories Prognosis. Treatment. SECTION 5. Conclusions. Bibliography. SECTION 1. INTRODUCTION. I think it can truthfully be said that the most interest­ ing problems in Medioine are those that are most baffling. Some years ago Ralph M a j o r ^ wrote these words, ”If our knowledge of the etiology of arterial hypertension is shrouded in a oertain haze, our knowledge of an effective therapy in this disease is enveloped in a dense fog.n A study of some of the vast literature on this subject does not greatly clarify the obscurity.
    [Show full text]
  • 441.2.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2018-eular.4790 on 12 June 2018. Downloaded from Scientific Abstracts Thursday, 14 June 2018 441 All GCA TAK p (n 23) (n 13) (n 8) Female, n (%) 19 (82.6) 12 (92.3) 6 (75) ns Age at diagnosis 63 (51–68) 68 (63–73) 43.5 (30.5–57) 0.003 Diagnostic latency (months) 4.5 (2–12) 3 (2–10) 8 (3.5–12) ns ESR at disease onset (mm/h) 49 (38–68) 52.5 (45.5– 42 (40–61.5) ns 59.7) CRP at disease onset (mg/L) 61.8 (13– 89 (32.5–106) 60.5 (9.3–132.5) ns 132.5) Disease duration at PET/MR 27 (18–36) 24 (13–29.5) 36.5 (14.75– ns (months) 129.3) ESR at examination (mm/h) 18 (9–35) 16 (7–31) 20.5 (11–44.5) ns CRP at examination (mg/L) 4.5 (2.55–8.9) 3.9 (3.48–4.72) 4.55 (2.05–10.4) ns Results: 23 LVV patients were included, 56.5% GCA, 34.8% TAK and 8.7% iso- Results: Among 602 patients with TA during this period, 119 (19.8%) were jTA, lated aortitis, all Caucasian, mostly females (82%). We considered 55 PET scans, while 483 were aTA. Female predominance was less striking in jTA (71.4%) than 32/55 in LVV group (from min. 1 to max. 3 scans/patient) mainly during follow-up aTA (79%), p=0.047. Patients with jTA had presented more commonly with fever (29/32 scans), and 23/55 in control group.
    [Show full text]
  • Echocardiography in Pediatric Pulmonary Hypertension
    REVIEW ARTICLE published: 12 November 2014 PEDIATRICS doi: 10.3389/fped.2014.00124 Echocardiography in pediatric pulmonary hypertension Pei-Ni Jone* and D. Dunbar Ivy Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA Edited by: Pulmonary hypertension (PH) can be a rapidly progressive and fatal disease. Although Antonio Francesco Corno, Universiti right heart catheterization remains the gold standard in evaluation of PH, echocardiogra- Sains Malaysia, Malaysia phy remains an important tool in screening, diagnosing, evaluating, and following these Reviewed by: Jeffrey Feinstein, Stanford University, patients. In this article, we will review the important echocardiographic parameters of the USA right heart in evaluating its anatomy, hemodynamic assessment, systolic, and diastolic Cecile Tissot, The University function in children with PH. Children’s Hospital, Switzerland Tilman Humpl, SickKids Hospital, Keywords: pediatric pulmonary hypertension, echocardiography, right heart, right ventricular function Canada *Correspondence: Pei-Ni Jone, Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado School of Medicine, 13123 East 16th Avenue, B100, Aurora, CO 80045, USA e-mail: pei-ni.jone@ childrenscolorado.org INTRODUCTION of the RA area in end-systole is performed to evaluate for RA dila- Pulmonary hypertension (PH) is a progressive disease that carries tion (Figure 1)(3). Indexed RA area to body surface area in adult high morbidity and mortality. Although cardiac catheterization is patients with idiopathic PH has been a predictor of mortality and used to define PH, echocardiography is the most important non- has been shown to be a prognostic marker for follow up of PH invasive tool that is used to detect PH (1).
    [Show full text]
  • Effects of Immediate Versus Delayed Antihypertensive Therapy on Outcome in the Systolic Hypertension in Europe Trial Jan A
    Original article 847 Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial Jan A. Staessena, Lutgarde Thijsa, Robert Fagarda, Hilde Celisa, Willem H. Birkenha¨gerb, Christopher J. Bulpittc, Peter W. de Leeuwd, Astrid E. Fletchere, Franc¸oise Forettef, Gastone Leonettig, Patricia McCormackh, Choudomir Nachevi, Eoin O’Brienh, Jose´ L. Rodicioj, Joseph Rosenfeldk, Cinzia Sartil, Jaakko Tuomilehtol, John Websterm, Yair Yodfatn and Alberto Zanchettig, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Background To assess the impact of immediate versus systolic hypertension. Immediate compared with delayed delayed antihypertensive treatment on the outcome of treatment prevented 17 strokes or 25 major cardiovascular older patients with isolated systolic hypertension, we events per 1000 patients followed up for 6 years. These extended the double-blind placebo-controlled Systolic findings underscore the necessity of early treatment of Hypertension in Europe (Syst-Eur) trial by an open-label isolated systolic hypertension. J Hypertens 22:847–857 & follow-up study lasting 4 years. 2004 Lippincott Williams & Wilkins. Methods The Syst-Eur trial included 4695 randomized Journal of Hypertension 2004, 22:847–857 patients with minimum age of 60 years and an untreated Keywords: calcium-channel blocker, clinical trial, isolated systolic blood pressure of 160–219 mmHg systolic and below hypertension, outcome, myocardial infarction, stroke 95 mmHg diastolic. The double-blind
    [Show full text]
  • Hypertension and the Prothrombotic State
    Journal of Human Hypertension (2000) 14, 687–690 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Hypertension and the prothrombotic state GYH Lip Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK The basic underlying pathophysiological processes related to conventional risk factors, target organ dam- underlying the major complications of hypertension age, complications and long-term prognosis, as well as (that is, heart attacks and strokes) are thrombogenesis different antihypertensive treatments. Further work is and atherogenesis. Indeed, despite the blood vessels needed to examine the mechanisms leading to this being exposed to high pressures in hypertension, the phenomenon, the potential prognostic and treatment complications of hypertension are paradoxically throm- implications, and the possible value of measuring these botic in nature rather than haemorrhagic. The evidence parameters in routine clinical practice. suggests that hypertension appears to confer a Journal of Human Hypertension (2000) 14, 687–690 prothrombotic or hypercoagulable state, which can be Keywords: hypercoagulable; prothrombotic; coagulation; haemorheology; prognosis Introduction Indeed, patients with hypertension are well-recog- nised to demonstrate abnormalities of each of these Hypertension is well-recognised to be an important 1 components of Virchow’s triad, leading to a contributor to heart attacks and stroke. Further- prothrombotic or hypercoagulable state.4 Further- more, effective antihypertensive therapy reduces more, the processes of thrombogenesis and athero- strokes by 30–40%, and coronary artery disease by 2 genesis are intimately related, and many of the basic approximately 25%. Nevertheless the basic under- concepts thrombogenesis can be applied to athero- lying pathophysiological processes underlying both genesis.
    [Show full text]
  • The Clinical Significance of Systolic Hypertension
    AJH 1998;11:182S–185S The Clinical Significance of Systolic Hypertension William C. Cushman Downloaded from https://academic.oup.com/ajh/article/11/S8/182S/151642 by guest on 28 September 2021 Large-scale epidemiologic studies and clinical trials Blood Pressure (JNC VI) recommends drug therapy have contributed to an increased recognition of the for all patients with stage 1 (140 to 159 mm Hg) or importance of systolic hypertension. Data from stage 2–3 (> 160 mm Hg) systolic hypertension, landmark epidemiologic studies such as the whether it occurs in isolation or in conjunction Multiple Risk Factor Intervention Trial screenee with diastolic hypertension. The sixth JNC report follow-up and the Framingham Heart Study have identified diuretics as the initial therapy of choice, demonstrated that elevated systolic blood pressure with a long-acting dihydropyridine calcium dramatically increases the risk of cardiovascular channel blocker as an alternative if diuretics are events. Of particular concern is the extremely high ineffective or not well tolerated. More research is risk associated with isolated systolic hypertension needed to evaluate other classes of drugs in this (ISH), which is much more common in the elderly setting. Regardless of the choice of therapy, than in young adults. Clinical trials have identified patients should be encouraged to adopt lifestyle significant risk reductions after treatment with modifications such as weight loss, exercise, sodium diuretics or the dihydropyridine calcium antagonist restriction, and reduced alcohol consumption. nitrendipine in older individuals with ISH. Beta Am J Hypertens 1998;11:182S–185S blockers have not been associated with such benefits. The recently released sixth report of the Joint National Committee on Prevention, KEY WORDS: Cardiovascular risk, systolic Detection, Evaluation, and Treatment of High hypertension.
    [Show full text]
  • The Burden of Pulmonary Hypertension in Resource-Limited Settings Suman Gidwani*, Ajith Nairy Durham, NC, USA; and New York, NY, USA
    j STATE-OF-THE-ART REVIEW gREVIEW The Burden of Pulmonary Hypertension in Resource-Limited Settings Suman Gidwani*, Ajith Nairy Durham, NC, USA; and New York, NY, USA ABSTRACT Pulmonary vascular disease (PVD) is a significant global health problem and accounts for a substantial portion of cardiovascular disease in the developing world. Although there have been considerable advances in therapeutics for pulmonary arterial hypertension, over 97% of the disease burden lies within the developing world where there is limited access to health care and pharmaceuticals. The causes of pulmonary arterial hypertension differ between industrialized and developing nations. Infectious diseases—including schistosomiasis human immunodeficiency virus, and rheumatic fever—are common causes of PVD, as are hemoglobinopathies, and untreated congenital heart disease. High altitude and exposure to household air pollutants also contribute to a significant portion of PVD cases. Although diagnosis of pulmonary arterial hypertension requires the use of imaging and invasive hemodynamics, access to equipment may be limited. PVD therapies may be prohibitively expensive and limited to a select few. Prevention is therefore important in limiting the global PVD burden. Cardiovascular disease accounts for roughly 30% of 2); PH secondary to pulmonary disease (group 3); chronic deaths worldwide and is the leading cause of death globally thromboembolic PH (group 4); and PH from multifactorial [1]. Pulmonary vascular disease (PVD) accounts for a sub- etiologies (group 5) [5] (Table 1). PAH represents a subset stantial burden of cardiovascular disease in resource-limited of PVD that is characterized by pre-capillary PVD. The settings. PVD broadly refers to any disorder that may affect hemodynamic definition of PAH is a mean PA pressure the pulmonary blood circulation.
    [Show full text]
  • The Study of Aortic Stiffness in Different Hypertension Subtypes in Dialysis Patients
    593 Hypertens Res Vol.31 (2008) No.4 p.593-599 Original Article The Study of Aortic Stiffness in Different Hypertension Subtypes in Dialysis Patients Li-Tao CHENG1),2), Hui-Min CHEN1),3), Li-Jun TANG1),4), Wen TANG1), Hai-Yan HUANG2), Yue GU1), and Tao WANG1),2) The aim of this study was to validate whether differences in aortic stiffness are responsible for the differ- ences in cardiovascular mortality among hypertension subtypes. Twenty hundred and fifty continuous ambulatory peritoneal dialysis patients were included in the present study. They were classified into four groups: normotensives (n=92) with systolic blood pressure (SBP) <140 mmHg and diastolic blood pressure (DBP) <90 mmHg; isolated systolic hypertensives (ISH, n=84) with SBP ≥140 mmHg and DBP <90 mmHg; isolated diastolic hypertensives (IDH, n=21) with SBP <140 mmHg and DBP ≥90 mmHg; and systolic-dias- tolic hypertensives (SDH, n=53) with SBP ≥140 mmHg and DBP ≥90 mmHg. Aortic stiffness was assessed by pulse pressure, central pressure parameters and pulse wave velocity. The IDH group had more male patients and a lower mean age than the other groups. The percentage of diabetes in the ISH group was higher than that in the other groups. The comparisons of aortic stiffness showed that the ISH and SDH groups had higher aortic stiffness than the normotension and IDH groups. The aortic stiffness in the ISH group was also higher than that in the SDH group, but there was no significant difference in aortic stiffness between the normotension and IDH groups. In conclusion, this study showed that aortic stiffness was sig- nificantly different among different hypertension subtypes, which might be an underlying cause of the dif- ferences in cardiovascular mortality among the hypertension subtypes.
    [Show full text]
  • Hypertension – the Silent Killer
    Journal of Pre-Clinical and Clinical Research, 2011, Vol 5, No 2, 43-46 REVIEW www.jpccr.eu Hypertension – The Silent Killer Katarzyna Sawicka1,2, Michał Szczyrek1, Iwona Jastrzębska1, Marek Prasał2, Agnieszka Zwolak1, Jadwiga Daniluk1 1 Chair of Internal Medicine and Department of Internal Medicine in Nursing, Medical University, Lublin, Poland 2 Department of Cardiology, Medical University, Lublin, Poland Abstract Hypertension is often called ‘the silent killer’ because it shows no early symptoms and, simultaneously, is the single most signifi cant risk factor for atherosclerosis and all clinical manifestations of atherosclerosis. It is an independent predisposing factor for heart failure, coronary artery disease, stroke, renal disease, and peripheral arterial disease. It is the most important risk factor for cardiovascular morbidity and mortality in industrialized countries. Key words hypertension, complications of hypertension INTRODUCTION diastolic blood pressure fall into diff erent categories, the highest category is used in assessing total cardiovascular Th e leading cause of mortality, responsible for roughly risk [1, 3]. one-third of all deaths globally, is cardiovascular disease. Th ere are 2 types of hypertension depending on etiology Th e majority of these events are caused not by one single – ‘primary’ (also called ‘essential’) hypertension and cardiovascular risk factor, but rather a mixture of several ‘secondary’ hypertension. Essential hypertension is the most factors. Th e most important of these in industrialized prevalent type, aff ecting 90-95% of hypertensive patients [4]. countries is not only hypertension, but also high levels of Th e pathogenesis of primary hypertension is multifactorial blood lipids, obesity, physical inactivity, smoking, glucose and complicated.
    [Show full text]
  • Redalyc.Cardiac Surgery and Hypertension: a Dangerous
    Revista Brasileira de Cirurgia Cardiovascular/Brazilian Journal of Cardiovascular Surgery ISSN: 0102-7638 [email protected] Sociedade Brasileira de Cirurgia Cardiovascular Brasil Yuan, Shi-Min; Jing, Hua Cardiac surgery and hypertension: a dangerous association that must be well known Revista Brasileira de Cirurgia Cardiovascular/Brazilian Journal of Cardiovascular Surgery, vol. 26, núm. 2, abril-junio, 2011, pp. 273-281 Sociedade Brasileira de Cirurgia Cardiovascular São José do Rio Preto, Brasil Available in: http://www.redalyc.org/articulo.oa?id=398941881019 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative ARTIGO DE REVISÃO Rev Bras Cir Cardiovasc 2011;26(2):273-81 Cardiac surgery and hypertension: a dangerous association that must be well known Cirurgia cardíaca e hipertensão: uma associação perigosa que deve ser bem conhecida Shi-Min YUAN1, Hua JING2 RBCCV 44205-1277 Abstract further discuss the possible etiologies and the potential It is well-known that hypertension is a very common treatment strategies so as to highlight the relevance at a disease, and severe cerebrovascular accidents might occur prognostic level. if the blood pressure is not properly controlled. However, conditions associated with uncontrolled hypertension may Descriptors: Cardiac Surgical Procedures. Heart Diseases. be overlooked, and may become critical and eventually Hypertension. require a surgical intervention on an urgent basis. Coronary artery disease, acute aortic syndrome, congenital and valvular heart disease, and arrhythmias are under this topic of discussion.
    [Show full text]
  • Assessment of the Acute Arterial Effects of Converting Enzyme Inhibition in Essential Hypertension: a Double-Blind, Comparative and Crossover Study
    Journal of Human Hypertension (1998) 12, 181–187 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 ORIGINAL ARTICLE Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study J Topouchian, AM Brisac, B Pannier, E Vicaut, M Safar and R Asmar Department of Internal Medicine and INSEM (U337) (U141), Broussais Hospital, Paris, France In subjects with essential hypertension, angiotensin- toward normal values. Carotid compliance and distens- converting enzyme (ACE) inhibition increases arterial ibility as well as aortic distensibility increased signifi- diameter, compliance and distensibility of peripheral cantly. Based on three-way analysis of variance, it was muscular arteries in association with blood pressure shown that, whereas the changes in carotid stiffness reduction. Whether pulse pressure amplification is were exclusively due to blood pressure reduction and modified by ACE inhibition and whether changes in not to a drug-induced relaxation of the arterial wall, the compliance and distensibility are due to a drug effect changes in aortic distensibility were due to the combi- on the arterial wall, to the blood pressure reduction or nation of both factors. Thus, using an atraumatic non- to a combination of both factors, is largely ignored. In invasive procedure, it was possible to show that: (i) ACE a randomised, double-blind crossover trial, we used the inhibition is able to maintain pulse pressure amplifi- ACE inhibitor quinapril as a marker to evaluate the cation, an important factor contributing to reduce the changes in: pulse pressure amplification (applanation afterload of the heart; and (ii) ACE inhibition alters the tonometry), carotid compliance and distensibility (echo- hypertensive arterial wall in a very heterogeneous man- tracking technique), and aortic distensibility (measured ner, with a maximal drug effect on muscular large from pulse wave velocity).
    [Show full text]
  • Hypertension and Coronary Heart Disease
    eJIFCC: www.ifcc.org/ejifcc 7. HYPERTENSION AND 7.1 The causes of high blood pressure CORONARY HEART DISEASE In most people, no specific cause of high blood pressure Dr Mirjana Cubrilo-Turek, MD, Ph.D. can be identified. It appears to be a distinct entity, due in part to a genetic predisposition (essential hyperten- sion). As much as 95% of the people with high blood Department of Internal Medicine, Sveti pressure have essential hypertension. The prob- Duh General Hospital, Zagreb ability of developing hypertension increases with age. More than half of all persons aged 65 are Hypertension is the most prevalent treatable cardiovascular hypertensive. Treating high blood pressure disease affecting approximately one in four adults or 140 significantly decreases the risk of stroke, myocar- million USA residents. It affects men and women in all dial infarction and cardiovascular death. Another socioeconomic groups equally. If untreated, hypertension type of high blood pressure called secondary is a major cause of stroke, coronary heart disease and hypertension is more common in younger indi- renal failure as well as other conditions. Easily diagnosed, viduals, usually due to some other problem (for and in most instances readily controlled, hypertension is example, persons taking birth control pills, often unsuspected or inadequately treated. renovascular patients, etc.). The causes of high blood pressure are a bit of a mystery. According to the National Heart, Lung and Blood Institute, 1 as many as 25% of adult Americans suffer from high blood Category Systolic Diastolic pressure. Results of the Croatian national survey per- formed in 1997 in a sample of 5840 persons of both Optimal <120 <80 sexes, aged 18-65, showed about 28% adults to be Normal <130 <85 hypertensive (BP>140/90 mm Hg), with a significantly High-normal 130-139 85-89 greater prevalence recorded in men (32%) than in women (24 %).
    [Show full text]